Exacis Biotherapeutics Presents Data On Its Stealth mRNA-engineered NK-cell Platform At American Society Of Gene & Cell Therapy Annual Meeting
Exacis produces its iPSC-derived ExaNK™ cells using its proprietary mRNA-based cell reprogramming and gene editing technologies